Amid challenges, the tobacco giant rethinks its healthcare leap, exploring partnerships to bolster the growth of its biggest pharma unit
20 September 2023 - 09:10
byChandni Shah and Kanjyik Ghosh
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Bengaluru — Marlboro-maker Philip Morris International (PMI) is considering selling a stake in Vectura, its biggest pharmaceutical unit, the Wall Street Journal (WSJ) reported on Tuesday.
The tobacco company told the Journal that it was looking to bring on a partner to help operate and grow Vectura’s drug manufacturing outsourcing business, and could possibly sell a majority or a minority stake.
Other options include a licensing or royalties deal or a commercial partnership, the report added.
A PMI spokesperson said the company did not have any comment to provide on the WSJ story.
Philip Morris bought UK-based Vectura, which makes asthma inhalers, for £1.1bn ($1.36bn) two years ago, saying it was part of its long-term plan to switch to being a “broader healthcare and wellness” company.
It also acquired nicotine gum-maker Fertin Pharma for over $800m and respiratory drug development company OtiTopic in the same year.
WSJ said that the tobacco giant has now had discussions with Deutsche Bank on a range of options to grow its healthcare and wellness division.
In the second quarter this year, Philip Morris booked a total impairment charge of $680m for the segment, and expected to postpone its 2025 target to reach over $1bn of net revenues due to issues with the unit.
“We aim to accelerate Vectura’s growth and will be exploring potential partnerships to enhance its contract development and manufacturing organisation business,” CFO Emmanuel Babeau had said in July, adding the company remained committed to developing the wellness healthcare segment.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Phillip Morris mulls Vectura stake sale
Amid challenges, the tobacco giant rethinks its healthcare leap, exploring partnerships to bolster the growth of its biggest pharma unit
Bengaluru — Marlboro-maker Philip Morris International (PMI) is considering selling a stake in Vectura, its biggest pharmaceutical unit, the Wall Street Journal (WSJ) reported on Tuesday.
The tobacco company told the Journal that it was looking to bring on a partner to help operate and grow Vectura’s drug manufacturing outsourcing business, and could possibly sell a majority or a minority stake.
Other options include a licensing or royalties deal or a commercial partnership, the report added.
A PMI spokesperson said the company did not have any comment to provide on the WSJ story.
Philip Morris bought UK-based Vectura, which makes asthma inhalers, for £1.1bn ($1.36bn) two years ago, saying it was part of its long-term plan to switch to being a “broader healthcare and wellness” company.
It also acquired nicotine gum-maker Fertin Pharma for over $800m and respiratory drug development company OtiTopic in the same year.
WSJ said that the tobacco giant has now had discussions with Deutsche Bank on a range of options to grow its healthcare and wellness division.
In the second quarter this year, Philip Morris booked a total impairment charge of $680m for the segment, and expected to postpone its 2025 target to reach over $1bn of net revenues due to issues with the unit.
“We aim to accelerate Vectura’s growth and will be exploring potential partnerships to enhance its contract development and manufacturing organisation business,” CFO Emmanuel Babeau had said in July, adding the company remained committed to developing the wellness healthcare segment.
Reuters
British American Tobacco sells Russian business to management
PHILIP SHORT: Scratching below the surface of tobacco companies
BAT posts rosy first-half profit due in part to pricier cigarettes
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
European airlines in pickle over ‘greenhushing’ cases
British American Tobacco sells Russian business to management
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.